{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=8",
    "query": {
      "intervention": "ribociclib",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 138,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T18:27:02.141Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04657679",
      "title": "Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2021-05-20",
      "completion_date": "2023-10-30",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04657679"
    },
    {
      "nct_id": "NCT03434262",
      "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma",
        "Anaplastic Ependymoma",
        "Anaplastic Ganglioglioma",
        "Anaplastic Meningioma",
        "Anaplastic Oligodendroglioma",
        "Pleomorphic Xanthoastrocytoma, Anaplastic",
        "Atypical Teratoid/Rhabdoid Tumor",
        "Brain Cancer",
        "Brain Tumor",
        "Central Nervous System Neoplasms",
        "Choroid Plexus Carcinoma",
        "CNS Embryonal Tumor With Rhabdoid Features",
        "Ganglioneuroblastoma of Central Nervous System",
        "CNS Tumor",
        "Embryonal Tumor of CNS",
        "Ependymoma",
        "Glioblastoma",
        "Glioma",
        "Glioma, Malignant",
        "Medulloblastoma",
        "Medulloblastoma; Unspecified Site",
        "Medulloepithelioma",
        "Neuroepithelial Tumor",
        "Neoplasms",
        "Neoplasms, Neuroepithelial",
        "Papillary Tumor of the Pineal Region (High-grade Only)",
        "Pediatric Brain Tumor",
        "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)",
        "Pineoblastoma",
        "Primitive Neuroectodermal Tumor",
        "Recurrent Medulloblastoma",
        "Refractory Brain Tumor",
        "Neuroblastoma. CNS",
        "Glioblastoma, IDH-mutant",
        "Glioblastoma, IDH-wildtype",
        "Medulloblastoma, Group 3",
        "Medulloblastoma, Group 4",
        "Glioma, High Grade",
        "Neuroepithelial Tumor, High Grade",
        "Medulloblastoma, SHH-activated and TP53 Mutant",
        "Medulloblastoma, SHH-activated and TP53 Wildtype",
        "Medulloblastoma, Chromosome 9q Loss",
        "Medulloblastoma, Non-WNT Non-SHH, NOS",
        "Medulloblastoma, Non-WNT/Non-SHH",
        "Medulloblastoma, PTCH1 Mutation",
        "Medulloblastoma, WNT-activated",
        "Ependymoma, Recurrent",
        "Glioma, Recurrent High Grade",
        "Glioma, Recurrent Malignant",
        "Embryonal Tumor, NOS",
        "Glioma, Diffuse Midline, H3K27M-mutant",
        "Embryonal Tumor With Multilayered Rosettes (ETMR)",
        "Ependymoma, NOS, WHO Grade III",
        "Ependymoma, NOS, WHO Grade II",
        "Medulloblastoma, G3/G4",
        "Ependymoma, RELA Fusion Positive"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "ribociclib",
          "type": "DRUG"
        },
        {
          "name": "sonidegib",
          "type": "DRUG"
        },
        {
          "name": "trametinib",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 68,
      "start_date": "2018-03-05",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2024-05-31",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03434262"
    },
    {
      "nct_id": "NCT05429502",
      "title": "Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 12,
      "start_date": "2022-12-27",
      "completion_date": "2025-02-26",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New Hyde Park, New York • Memphis, Tennessee",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05429502"
    },
    {
      "nct_id": "NCT04000529",
      "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Esophageal SCC",
        "Gastrointestinal Stromal Tumors",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "TNO155",
          "type": "DRUG"
        },
        {
          "name": "Spartalizumab",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2019-07-30",
      "completion_date": "2024-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04000529"
    },
    {
      "nct_id": "NCT06344416",
      "title": "Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Any Solid Oral Medication"
      ],
      "interventions": [
        {
          "name": "Use of ReX to dispense and monitor solid oral medication therapy.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Dosentrx Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-03-30",
      "completion_date": "2026-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-03-12",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 4,
      "location_summary": "Minneapolis, Minnesota • Austin, Texas • Richmond, Virginia + 1 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06344416"
    },
    {
      "nct_id": "NCT02607124",
      "title": "A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "Diffuse Intrinsic Pontine Glioma",
        "Bithalamic High Grade Glioma"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 11,
      "start_date": "2016-04",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2020-11-05",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02607124"
    },
    {
      "nct_id": "NCT03616587",
      "title": "Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ER+ HER2- Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AZD9833",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with palbociclib",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with everolimus",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with capivasertib",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with ribociclib",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with anastrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 396,
      "start_date": "2018-10-11",
      "completion_date": "2027-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03616587"
    },
    {
      "nct_id": "NCT02187783",
      "title": "LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumors With CDK4/6 Pathway Activation"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2014-08-25",
      "completion_date": "2018-01-17",
      "has_results": true,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pismo Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02187783"
    },
    {
      "nct_id": "NCT02388620",
      "title": "Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Hepatic Function",
        "Impaired Hepatic Function"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2015-03-25",
      "completion_date": "2017-01-09",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Coral Gables, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02388620"
    },
    {
      "nct_id": "NCT01543698",
      "title": "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors Harboring a BRAF V600 Mutation"
      ],
      "interventions": [
        {
          "name": "LGX818",
          "type": "DRUG"
        },
        {
          "name": "MEK162",
          "type": "DRUG"
        },
        {
          "name": "LEE011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 189,
      "start_date": "2012-05-28",
      "completion_date": "2023-03-09",
      "has_results": true,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-10-17T18:27:02.141Z",
      "location_count": 6,
      "location_summary": "Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543698"
    }
  ]
}